• Arshiya Shamim Department of Pharmacy, Integral University, Lucknow, Uttar Pradesh, India
  • Hefazat Hussain Siddiqui Department of Pharmacy, Integral University, Lucknow, Uttar Pradesh, India
  • Tarique Mahmood Department of Pharmacy, Integral University, Lucknow, Uttar Pradesh, India
  • Paramdeep Bagga Department of Pharmacy, Integral University, Lucknow, Uttar Pradesh, India
  • Ranjan Kumar Department of Pharmacy, Integral University, Lucknow, Uttar Pradesh, India




Cardiomyopathy, Diabetes, Herbal treatment, Neuropathy, Neuropathic pain, Oxidative stress, Ventricular hypertrophy



 Diabetes mellitus is a worldwide epidemic disease that eventually advances to a chronic stage and affects different vital organs by intensifying the underlying pathological factors, and through the remodeling of the tissues by the generation of reactive oxygen species leading to the development of respective organ failure. Two such complications are painful neuropathy and cardiomyopathy; both of which are common and progressive complications of diabetes. The symptoms of peripheral neuropathy include tingling, burning, lancinating pain, hyperesthesia, and allodynia. The course of the disease progression may vary from intermittent, mild symptoms to severe chronic, and daily pain; which culminates into poor quality of life. Another complication of diabetes mellitus, diabetic cardiomyopathy, is defined as a ventricular dysfunction disorder that occurs in diabetic patients. The development of the disease is characterized by a hidden subclinical period, during which cellular, structural changes and abnormalities lead to diastolic dysfunction, followed by systolic dysfunction, and terminating into heart failure. Left ventricular hypertrophy, metabolic abnormalities, extracellular matrix changes, small vessel disease, cardiac autonomic neuropathy, insulin resistance, oxidative stress, and apoptosis are the most important pathological advancements that lead to diabetic cardiomyopathy. Various pharmaceutical agents from different pharmacological categories have been proposed for the symptomatic treatment of painful diabetic neuropathy; however, it is a herculean task to select a drug due to the wide range of choices and lack of consistent guidelines for treatment. Similarly, treatment of cardiomyopathy is based on the general therapeutic rules of management of heart failure and no specifications have yet been addressed for this condition. Therefore, more studies are required to improve our knowledge of these complex syndromes. From this perspective, this review is designed to delineate a general overview of neuropathy and cardiomyopathy, referring to the conventional therapies in use and possible unconventional, natural, herbal, and safe treatments for both the above-mentioned complications of diabetes.


Download data is not yet available.

Author Biographies

Arshiya Shamim, Department of Pharmacy, Integral University, Lucknow, Uttar Pradesh, India

Lecturer and Research scholar at F/O Pharmacy,Integral University

Hefazat Hussain Siddiqui, Department of Pharmacy, Integral University, Lucknow, Uttar Pradesh, India

Adjunct Professor (Dr.), F/O Pharmacy, Integral University

Tarique Mahmood, Department of Pharmacy, Integral University, Lucknow, Uttar Pradesh, India

Associate professor & HOD, F/O Pharmacy, Integral Universitry

Paramdeep Bagga, Department of Pharmacy, Integral University, Lucknow, Uttar Pradesh, India

Assistant Professor, F/O pharmacy, Integral University

Ranjan Kumar, Department of Pharmacy, Integral University, Lucknow, Uttar Pradesh, India

Assistant Professor, F/O pharmacy, Integral University


Narayan KM, Gregg EW, Fagot-Campagna A, Engelgau MM, Vinicor F. Diabetes-a common, growing, serious, costly, and potentially preventable public health problem. Diabetes Res Clin Pract 2000;50:S77-84.

Zatalia SR, Sanusi H. The role of antioxidants in the pathophysiology, complications, and management of diabetes mellitus. Acta Med Indones 2013;45:141-7.

Diabetes - A Global Threat. Available from: http://www.thelancet. com/journals/lancet/article/PIIS0140-6736(09)60954-5/fulltext. [Last accessed on 2014 Mar 03].

Patel A, Chalmers J, Poulter N. ADVANCE: Action in diabetes and vascular disease. J Hum Hypertens 2005;19 Suppl 1:S27-32.

WHO maps noncommunicable disease trends in all countries: Country profiles on noncommunicable disease trends in 193 countries. Cent Eur J Public Health 2011;19(3):130, 138.

Chang CL, Lin Y, Bartolome AP, Chen YC, Chiu SC, Yang WC. Herbal therapies for Type 2 diabetes mellitus: Chemistry, biology, and potential application of selected plants and compounds. Evid Based Complement Alternat Med 2013;2013:378657.

Espelt A, Borrell C, Palència L, Goday A, Spadea T, Gnavi R, et al. Socioeconomic inequalities in the incidence and prevalence of Type 2 diabetes mellitus in Europe. Gac Sanit 2013;27(6):494-501.

Kuritzky L. Managing diabetic peripheral neuropathic pain in primary care. J Fam Pract 2010;59 5 Suppl: S15-22.

Ko SH, Kwon HS, Yu JM, Baik SH, Park IB, Lee JH, et al. Comparison of the efficacy and safety of tramadol/acetaminophen combination therapy and gabapentin in the treatment of painful diabetic neuropathy. Diabet Med 2010;27(9):1033-40.

Baruah MP, Kalra S, Ranabir S. Metformin; A character actor in the leptin story! Indian J Endocrinol Metab 2012;16 Suppl 3:S532-3.

Tyagi N, Goel R. Models for neuropathic pain: A review. Int J Pharm Pharm Sci 2014;6:36-9.

Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in Type 2 diabetes. Diabetes Care 2006;29(7):1518-22.

Ziegler D, Ametov A, Barinov A, Dyck PJ, Gurieva I, Low PA, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: The SYDNEY 2 trial. Diabetes Care 2006;29(11):2365-70.

Huizinga MM, Peltier A. Painful diabetic neuropathy: A management-centered review. Clin Diabetes 2007;25:6-15.

Said G. Diabetic neuropathy-a review. Nat Clin Pract Neurol 2007;3(6):331-40.

Gordois A, Scuffham P, Shearer A, Oglesby A, Tobian JA. The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care 2003;26(6):1790-5.

Gore M, Brandenburg NA, Hoffman DL, Tai KS, Stacey B. Burden of illness in painful diabetic peripheral neuropathy: The patients’ perspectives. J Pain 2006;7(12):892-900.

Gore M, Sadosky A, Leslie D, Sheehan AH. Selecting an appropriate medication for treating neuropathic pain in patients with diabetes: A study using the U.K. and Germany Mediplus databases. Pain Pract 2008;8(4):253-62.

Van Acker K, Bouhassira D, De Bacquer D, Weiss S, Matthys K, Raemen H, et al. Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in Type 1 and Type 2 diabetic patients attending hospital outpatients clinics. Diabetes Metab 2009;35(3):206-13.

Daniell HW. Hypogonadism in men consuming sustained-action oral opioids. J Pain 2002;3(5):377-84.

Lee C, Ludwig S, Duerksen DR. Low serum cortisol associated with opioid use: Case report and review of the literature. Endocrinologist 2002;12:5-8.

Risdahl JM, Khanna KV, Peterson PK, Molitor TW. Opiates and infection. J Neuroimmunol 1998;83(1-2):4-18.

Sandercock D, Cramer M, Wu J, Chiang YK, Biton V, Heritier M. Gabapentin extended release for the treatment of painful diabetic peripheral neuropathy: Efficacy and tolerability in a double-blind, randomized, controlled clinical trial. Diabetes Care 2009;32:e20.

Sindrup SH, Bach FW, Madsen C, Gram LF, Jensen TS. Venlafaxine versus imipramine in painful polyneuropathy: A randomized, controlled trial. Neurology 2003;60(8):1284-9.

Bansal D, Bhansali A, Hota D, Chakrabarti A, Dutta P. Amitriptyline versus Pregabalin in painful diabetic neuropathy: A randomized double blind clinical trial. Diabetes Med 2009;26:1019-26.

Morello CM, Leckband SG, Stoner CP, Moorhouse DF, Sahagian GA. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med 1999;159(16):1931-7.

Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992;326(19):1250-6.

Armstrong DG, Chappell AS, Le TK, Kajdasz DK, Backonja M, D’Souza DN, et al. Duloxetine for the management of diabetic peripheral neuropathic pain: Evaluation of functional outcomes. Pain Med 2007;8(5):410-8.

Wernicke JF, Pritchett YL, D’Souza DN, Waninger A, Tran P, Iyengar S, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 2006;67(8):1411-20.

Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005;116(1-2):109-18.

Raskin J, Pritchett YL, Wang F, D’Souza DN, Waninger AL, Iyengar S, et al. A double blind randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 2005;6:346-56.

Rowbotham MC, Goli V, Kunz NR, Lei D. Venlafaxine extended release in the treatment of painful diabetic neuropathy: A double-blind, placebo-controlled study. Pain 2004;110(3):697-706.

Agrawal RP, Goswami J, Jain S, Kochar DK. Management of diabetic neuropathy by sodium valproate and glyceryl trinitrate spray: A prospective double-blind randomized placebo-controlled study. Diabetes Res Clin Pract 2009;83(3):371-8.

Jose VM, Bhansali A, Hota D, Pandhi P. Randomized double-blind study comparing the efficacy and safety of lamotrigine and amitriptyline in painful diabetic neuropathy. Diabet Med 2007;24(4):377-83.

Vinik AI, Tuchman M, Safirstein B, Corder C, Kirby L, Wilk K, et al. Lamotrigine for treatment of pain associated with diabetic neuropathy: Results of two randomized, double-blind, placebo-controlled studies. Pain Med 2007;128:169-79.

McCleane G. 200 mg daily of lamotrigine has no analgesic effect in neuropathic pain: A randomised, double-blind, placebo controlled trial. Pain 1999;83(1):105-7.

Beydoun A, Shaibani A, Hopwood M, Wan Y. Oxcarbazepine in painful diabetic neuropathy: Results of a dose-ranging study. Acta Neurol Scand 2006;113(6):395-404.

Dogra S, Beydoun S, Mazzola J, Hopwood M, Wan Y. Oxcarbazepine in painful diabetic neuropathy: A randomized, placebo-controlled study. Eur J Pain 2005;9(5):543-54.

Grosskopf J, Mazzola J, Wan Y, Hopwood M. A randomized, placebo-controlled study of oxcarbazepine in painful diabetic neuropathy. Acta Neurol Scand 2006;114(3):177-80.

Reljanovic M, Reichel G, Rett K, Lobisch M, Schuette K, Möller W, et al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): A two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha lipoic acid in diabetic neuropathy. Free Radic Res 1999;31(3):171-9.

Hovaguimian A, Gibbons CH. Clinical approach to the treatment of painful diabetic neuropathy. Ther Adv Endocrinol Metab 2011;2(1):27-38.

Trachanas K, Sideris S, Aggeli C, Poulidakis E, Gatzoulis K, Tousoulis D, et al. Diabetic cardiomyopathy: From pathophysiology to treatment. Hellenic J Cardiol 2014;55(5):411-21.

Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 1972;30(6):595-602.

Ravindra P, Vanishree S, Sujatha S, Kishore K. Effect of carvedilol on pharmacokinetics and pharmacodynamics of glipizide. Int J Pharm Pharm Sci 2012;4(3):133-8.

Devereux RB, Roman MJ, Paranicas M, O’Grady MJ, Lee ET, Welty TK, et al. Impact of diabetes on cardiac structure and function: The strong heart study. Circulation 2000;101(19):2271-6.

Eguchi K, Boden-Albala B, Jin Z, Rundek T, Sacco RL, Homma S, et al. Association between diabetes mellitus and left ventricular hypertrophy in a multiethnic population. Am J Cardiol 2008;101(12):1787-91.

Woodiwiss AJ, Libhaber CD, Majane OH, Libhaber E, Maseko M, Norton GR. Obesity promotes left ventricular concentric rather than eccentric geometric remodeling and hypertrophy independent of blood pressure. Am J Hypertens 2008;21(10):1144-51.

Barouch LA, Berkowitz DE, Harrison RW, O’Donnell CP, Hare JM. Disruption of leptin signalling contributes to cardiac hypertrophy independently of body weight in mice. Circulation 2003;108(6):754-9.

Xu FP, Chen MS, Wang YZ, Yi Q, Lin SB, Chen AF, et al. Leptin induces hypertrophy via endothelin-1-reactive oxygen species pathway in cultured neonatal rat cardiomyocytes. Circulation 2004;110(10):1269-75.

Boudina S, Sena S, Theobald H, Sheng X, Wright JJ, Hu XX, et al. Mitochondrial energetics in the heart in obesity-related diabetes: Direct evidence for increased uncoupled respiration and activation of uncoupling proteins. Diabetes 2007;56(10):2457-66.

Bugger H, Boudina S, Hu XX, Tuinei J, Zaha VG, Theobald HA, et al. Type 1 diabetic Akita mouse hearts are insulin sensitive but manifest structurally abnormal mitochondria that remain coupled despite increased uncoupling protein 3. Diabetes 2008;57(11):2924-32.

Boudina S, Bugger H, Sena S, O’Neill BT, Zaha VG, Ilkun O, et al. Contribution of impaired myocardial insulin signaling to mitochondrial dysfunction and oxidative stress in the heart. Circulation 2009;119(9):1272-83.

Regan TJ, Lyons MM, Ahmed SS, Levinson GE, Oldewurtel HA, Ahmad MR, et al. Evidence for cardiomyopathy in familial diabetes mellitus. J Clin Invest 1977;60(4):884-99.

Shimizu M, Umeda K, Sugihara N, Yoshio H, Ino H, Takeda R, et al. Collagen remodelling in myocardia of patients with diabetes. J Clin Pathol 1993;46(1):32-6.

Mizushige K, Yao L, Noma T, Kiyomoto H, Yu Y, Hosomi N, et al. Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. Circulation 2000;101(8):899-907.

Ernande L, Bergerot C, Rietzschel ER, De Buyzere ML, Thibault H, Pignonblanc PG, et al. Diastolic dysfunction in patients with Type 2 diabetes mellitus: Is it really the first marker of diabetic cardiomyopathy? J Am Soc Echocardiogr 2011;24(11):1268-75.e1.

Picano E, Pelosi G, Marzilli M, Lattanzi F, Benassi A, Landini L, et al. In vivo quantitative ultrasonic evaluation of myocardial fibrosis in humans. Circulation 1990;81(1):58-64.

Pérez JE, McGill JB, Santiago JV, Schechtman KB, Waggoner AD, Miller JG, et al. Abnormal myocardial acoustic properties in diabetic patients and their correlation with the severity of disease. J Am Coll Cardiol 1992;19(1):1154-62.

Di Bello V, Talarico L, Picano E, Di Muro C, Landini L, Paterni M, et al. Increased echodensity of myocardial wall in the diabetic heart: An ultrasound tissue characterization study. J Am Coll Cardiol 1995;25(6):1408-15.

Kwong RY, Sattar H, Wu H, Vorobiof G, Gandla V, Steel K, et al. Incidence and prognostic implication of unrecognized myocardial scar characterized by cardiac magnetic resonance in diabetic patients without clinical evidence of myocardial infarction. Circulation 2008;118(10):1011-20.

McGavock JM, Lingvay I, Zib I, Tillery T, Salas N, Unger R, et al. Cardiac steatosis in diabetes mellitus: A 1H-magnetic resonance spectroscopy study. Circulation 2007;116(10):1170-5.

Rijzewijk LJ, van der Meer RW, Smit JW, Diamant M, Bax JJ, Hammer S, et al. Myocardial steatosis is an independent predictor of diastolic dysfunction in Type 2 diabetes mellitus. J Am Coll Cardiol 2008;52(22):1793-9.

Ng AC, Delgado V, Bertini M, van der Meer RW, Rijzewijk LJ, Hooi Ewe S, et al. Myocardial steatosis and biventricular strain and strain rate imaging in patients with Type 2 diabetes mellitus. Circulation 2010;122(24):2538-44.

Miki T, Yuda S, Kouzu H, Miura T. Diabetic cardiomyopathy: Pathophysiology and clinical features. Heart Fail Rev 2013;18(2):149-66.

Torffvit O, Lövestam-Adrian M, Agardh E, Agardh CD. Nephropathy, but not retinopathy, is associated with the development of heart disease in Type 1 diabetes: A 12-year observation study of 462 patients. Diabet Med 2005;22(6):723-9.

From AM, Leibson CL, Bursi F, Redfield MM, Weston SA, Jacobsen SJ, et al. Diabetes in heart failure: Prevalence and impact on outcome in the population. Am J Med 2006;119(7):591-9.

Bell DS. Heart failure: The frequent, forgotten, and often fatal complication of diabetes. Diabetes Care 2003;26(8):2433-41.

Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC, et al. Intensive glucose control and macrovascular outcomes in Type 2 diabetes. Diabetologia 2009;52:2288-98.

von Bibra H, Hansen A, Dounis V, Bystedt T, Malmberg K, Rydén L. Augmented metabolic control improves myocardial diastolic function and perfusion in patients with non-insulin dependent diabetes. Heart 2004;90(12):1483-4.

Hordern MD, Coombes JS, Cooney LM, Jeffriess L, Prins JB, Marwick TH. Effects of exercise intervention on myocardial function in Type 2 diabetes. Heart 2009;95(16):1343-9.

Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with Type 2 diabetes. N Engl J Med 2003;348(5):383-93.

Andersson C, Olesen JB, Hansen PR, Weeke P, Norgaard ML, Jørgensen CH, et al. Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: A retrospective nationwide cohort study. Diabetologia 2010;53(12):2546-53.

Tang WH, Francis GS, Hoogwerf BJ, Young JB. Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure. J Am Coll Cardiol 2003;41(1):1394-8.

Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: An observational study.

Circulation 2005;111(5):583-90.

Aguilar D, Bozkurt B, Pritchett A, Petersen NJ, Deswal A. The impact of thiazolidinedione use on outcomes in ambulatory patients with diabetes mellitus and heart failure. J Am Coll Cardiol 2007;50(1):32-6.

Erdmann E, Wilcox RG. Weighing up the cardiovascular benefits of thiazolidinedione therapy: The impact of increased risk of heart failure. Eur Heart J 2008;29(1):12-20.

Horio T, Suzuki M, Suzuki K, Takamisawa I, Hiuge A, Kamide K, et al. Pioglitazone improves left ventricular diastolic function in patients with essential hypertension. Am J Hypertens 2005;18(7):949-57.

van der Meer RW, Rijzewijk LJ, de Jong HW, Lamb HJ, Lubberink M, Romijn JA, et al. Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled Type 2 diabetes mellitus. Circulation 2009;119(15):2069-77.

Kodama S, Tanaka S, Heianza Y, Fujihara K, Horikawa C, Shimano H, et al. Association between physical activity and risk of all-cause mortality and cardiovascular disease in patients with diabetes: A meta-analysis. Diabetes Care 2013;36:471-9.

Sharma AK, Srinivasan BP. Triple verses glimepiride plus metformin therapy on cardiovascular risk biomarkers and diabetic cardiomyopathy in insulin resistance type 2 diabetes mellitus rats. Eur J Pharm Sci 2009;38(5):433-44.

Xie Z, Lau K, Eby B, Lozano P, He C, Pennington B, et al. Improvement of cardiac functions by chronic metformin treatment is associated with enhanced cardiac autophagy in diabetic OVE26 mice. Diabetes 2011;60(6):1770-8.

Eurich DT, McAlister FA, Blackburn DF, Majumdar SR, Tsuyuki RT, Varney J, et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: Systematic review. BMJ 2007;335(7618):497.

Aguilar D, Chan W, Bozkurt B, Ramasubbu K, Deswal A. Metformin use and mortality in ambulatory patients with diabetes and heart failure. Circ Heart Fail 2011;4(1):53-8.

Abesundara KJ, Matsui T, Matsumoto K. Alpha-glucosidase inhibitory activity of some Sri Lanka plant extracts, one of which, Cassia auriculata, exerts a strong antihyperglycemic effect in rats comparable to the therapeutic drug acarbose. J Agric Food Chem 2004;52:2541-5.

Joseph B, Jini D. An insight in hypoglycaemia effect of traditional Indian herbs used in the treatment of diabetes. Res J Med Plant 2011;5:352-76.

Shindler DM, Kostis JB, Yusuf S, Quinones MA, Pitt B, Stewart D, et al. Diabetes mellitus, a predictor of morbidity and mortality in the studies of left ventricular dysfunction (SOLVD) trials and registry. Am J Cardiol 1996;77(11):1017-20.

Rydén L, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Packer M, et al. Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. Eur Heart J 2000;21(21):1967-78.

Komajda M, Carson PE, Hetzel S, McKelvie R, McMurray J, Ptaszynska A, et al. Factors associated with outcome in heart failure with preserved ejection fraction: Findings from the irbesartan in heart failure with preserved ejection fraction study (I-PRESERVE). Circ Heart Fail 2011;4(1):27-35.

Vermes E, Ducharme A, Bourassa MG, Lessard M, White M, Tardif JC; Studies of Left Ventricular Dysfunction. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: Insight from the studies of left ventricular dysfunction (SOLVD). Circulation 2003;107(9):1291-6.

Dickstein K, Kjekshus J; OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: The OPTIMAAL randomised trial. Optimal trial in myocardial infarction with angiotensin II antagonist losartan. Lancet 2002;360(3935):752-60.

Haas SJ, Vos T, Gilbert RE, Krum H. Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. Am Heart J 2003;146(5):848-53.

de Boer RA, Doehner W, van der Horst IC, Anker SD, Babalis D, Roughton M, et al. SENIORS investigators. Influence of diabetes mellitus and hyperglycaemia on prognosis in patients > or =70 years old with heart failure and effects of nebivolol (data from the study of effects of nebivolol intervention on outcomes and rehospitalisation in seniors with heart failure [SENIORS]). Am J Cardiol 2010;106:78-86.

Deedwania PC, Giles TD, Klibaner M, Ghali JK, Herlitz J, Hildebrandt P, et al. Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: Experiences from MERIT-HF. Am Heart J 2005;149(41):159-67.

The cardiac insufficiency bisoprolol study II (CIBIS-II): A randomised trial. Lancet 1999;353(9146):9-13.

Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344(22):1651-8.

Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: The Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 2000;283(10):1295-302.

Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol European trial (COMET): Randomised controlled trial. Lancet 2003;362(9377):7-13.

Shorr RI, Ray WA, Daugherty JR, Griffin MR. Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas. JAMA 1997;278(1):40-3.

Kostis JB, Sanders M. The association of heart failure with insulin resistance and the development of Type 2 diabetes. Am J Hypertens 2005;18:731-7.

Fernandez HM, Leipzig RM. Spironolactone in patients with heart failure. N Engl J Med 2000;342(2):132.

Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): A randomised placebo-controlled study. Lancet 2010;376(9744):875 85.

Parabathina RK, Murlinath E, Swami LP, Krishnahari VV. Potential effect of vitamin E, morin, rutin and quercetin against doxorubicin induced cardiomyopathy. Int J Pharm Pharm Sci 2011;3(4):280-4.

Nagilla B, Reddy P. Neuroprotective and anti-nociceptive effect of curcumin in diabetic neuropathy in rats. Int J Pharm Pharm Sci 2014;6(5):1331-8.

Dixit PP, Londhe JS, Ghaskadbi SS, Devasagayam TP. Antidiabetic and related beneficial properties of Indian medicinal plants. In: Herbal Drug Research - A Twenty First Century Perspectives. New Delhi, India: Jaypee Brothers Medical Publishers Limited; 2006. p. 377-86.

Wadood A, Wadood N, Shah SA. Effects of Acacia arabica and Caralluma edulis on blood glucose levels of normal and alloxan diabetic rabbits. J Pak Med Assoc 1989;39(8):208-12.

Chattopadhyay RR, Chattopadhyay RN, Nandy AK, Poddar G, Maitra SK. Preliminary report on anti-hyperglycaemic effect of fraction of fresh leaves of Azadiracta indica (Beng neem). Bull Calcutta Sch Trop Med 1987;35:29-33.

Chattopadhyay RR, Chattopadhyay RN, Nandy AK, Poddar G, Maitra SK. The effect of fresh leaves of Azadiracta indica on glucose uptake and glycogen content in the isolated rat hemi diaphragm. Bull Calcutta Sch Trop Med 1987;35:8-12.

Biswas K, Chattopadhyay I, Banerjee RK, Bandyopadhyay U. Biological activities and medicinal properties of neem (Azadiracta indica). Curr Sci 2002;82:1336-45.

Khanna P, Jain SC, Panagariya A, Dixit VP. Hypoglycaemic activity of polypeptide-p from a plant source. J Nat Prod 1981;44:648-55.

Stanely Mainzen Prince P, Menon VP. Hypoglycaemic and hypolipidaemic action of alcohol extract of Tinospora cordifolia roots in chemical induced diabetes in rats. Phytother Res 2003;17(4):410-3.

Stanely M, Prince P, Menon VP. Antioxidant action of Tinospora cordifolia root extract in alloxan diabetic rats. Phytother Res 2001;15:213-8.

Prince PS, Menon VP. Antioxidant activity of Tinospora cordifolia roots in experimental diabetes. J Ethnopharmacol 1999;65(3):277-81.

Mathew S, Kuttan G. Antioxidant activity of Tinospora cordifolia and its usefulness in the amelioration of cyclophosphamide induced toxicity. J Exp Clin Cancer Res 1997;16(4):407-11.



How to Cite

Shamim, A., H. H. Siddiqui, T. Mahmood, P. Bagga, and R. Kumar. “A COMPREHENSIVE STUDY ON LITERATURE EVIDENCE, CLINICAL STUDIES AND PRACTICES OF HERBAL DRUGS FOR DIABETIC NEUROPATHY AND CARDIOMYOPATHY”. Asian Journal of Pharmaceutical and Clinical Research, vol. 10, no. 9, Sept. 2017, pp. 30-37, doi:10.22159/ajpcr.2017.v10i9.18785.



Review Article(s)